Moreover, CCL3−/− mice showed significantly reduced hepatic and serum triglyceride levels when compared to CCL3+/+ mice (Figure S1A and B, P<0.05), suggesting that CCL3 might also operate in metabolic disease. This evidence concerns the gene CCL3 and Other metabolic disease.